Center for Perinatal Research, The Research Institute at Nationwide Children's Hospital, Department of Pediatric Surgery, Nationwide Children's Hospital , Columbus, Ohio.
Center for Microbial Pathogenesis, The Research Institute at Nationwide Children's Hospital , Columbus, Ohio.
Am J Physiol Gastrointest Liver Physiol. 2018 Sep 1;315(3):G408-G419. doi: 10.1152/ajpgi.00078.2018. Epub 2018 May 31.
One significant drawback of current probiotic therapy for the prevention of necrotizing enterocolitis (NEC) is the need for at least daily administration because of poor probiotic persistence after enteral administration, increasing the risk of the probiotic bacteria causing bacteremia or sepsis if the intestines are already compromised. We previously showed that the effectiveness of Lactobacillus reuteri ( Lr) in preventing NEC is enhanced when Lr is grown as a biofilm on the surface of dextranomer microspheres (DM). Here we sought to test the efficacy of Lr administration by manipulating the Lr biofilm state with the addition of biofilm-promoting substances (sucrose and maltose) to DM or by mutating the Lr gtfW gene (encoding an enzyme central to biofilm production). Using an animal model of NEC, we determined that Lr adhered to sucrose- or maltose-loaded DM significantly reduced histologic injury, improved host survival, decreased intestinal permeability, reduced intestinal inflammation, and altered the gut microbiome compared with Lr adhered to unloaded DM. These effects were abolished when DM or GtfW were absent from the Lr inoculum. This demonstrates that a single dose of Lr in its biofilm state decreases NEC incidence. Importantly, preloading DM with sucrose or maltose further enhances Lr protection against NEC in a GtfW-dependent fashion, demonstrating the tunability of the approach and the potential to use other cargos to enhance future probiotic formulations. NEW & NOTEWORTHY Previous clinical trials of probiotics to prevent necrotizing enterocolitis have had variable results. In these studies, probiotics were delivered in their planktonic, free-living form. We have developed a novel probiotic delivery system in which Lactobacillus reuteri (Lr) is delivered in its biofilm state. In a model of experimental necrotizing enterocolitis, this formulation significantly reduces intestinal inflammation and permeability, improves survival, and preserves the natural gut microflora compared with the administration of Lr in its free-living form.
当前用于预防坏死性小肠结肠炎 (NEC) 的益生菌疗法存在一个显著缺陷,即由于经肠道给药后益生菌的持续存在效果不佳,需要至少每天给药,这增加了益生菌细菌如果肠道已经受损,导致菌血症或败血症的风险。我们之前表明,当将罗伊氏乳杆菌 (Lr) 培养为葡聚糖微球 (DM) 表面的生物膜时,Lr 预防 NEC 的效果会增强。在这里,我们通过向 DM 中添加生物膜促进物质(蔗糖和麦芽糖)或通过突变 Lr gtfW 基因(编码生物膜生成的关键酶)来操纵 Lr 生物膜状态,从而测试了 Lr 给药的功效。使用 NEC 的动物模型,我们确定 Lr 黏附在负载蔗糖或麦芽糖的 DM 上可显著减少组织学损伤,提高宿主存活率,降低肠道通透性,减少肠道炎症,并改变肠道微生物组,与黏附在未加载 DM 的 Lr 相比。当 DM 或 GtfW 从 Lr 接种物中缺失时,这些作用被消除。这表明,处于生物膜状态的单次 Lr 剂量可降低 NEC 的发病率。重要的是,用蔗糖或麦芽糖预加载 DM 可进一步以 GtfW 依赖的方式增强 Lr 对 NEC 的保护作用,这证明了该方法的可调节性,并且有可能使用其他载体来增强未来的益生菌配方。新的和值得注意的是:以前预防坏死性小肠结肠炎的益生菌临床试验结果各不相同。在这些研究中,益生菌以浮游、自由生活的形式给药。我们开发了一种新的益生菌输送系统,其中罗伊氏乳杆菌 (Lr) 以生物膜状态输送。在实验性坏死性小肠结肠炎模型中,与以自由生活形式给予 Lr 相比,这种制剂可显著减少肠道炎症和通透性,提高存活率,并保留天然肠道微生物群。